Seattle, WA. – January 9, 2008 – Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co-lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: email@example.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros’ proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros’ actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros’ clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.